Bloomberg News

Evotec Reports Second Multi-Target Collaboration With UCB

October 05, 2011

Oct. 5 (Bloomberg) -- Evotec AG entered into a second multi-year, multi-target drug discovery cooperation with UCB SA in the field of immunology. Evotec will identfy small molecules against a selected number of targets.

Evotec will receive research funding based on the resource allocated over the projects and will be further rewarded on achieving the goals with early stage discovery, preclinical and clinical milestones. Evotec will also receive royalties based on net sales of any approved drugs.

Link to Statement:{NSN LSKVAU3PR6RK <GO>}

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus